SNDX- Syndax Pharmaceuticals, Inc.
Syndax Pharmaceuticals, Inc. (SNDX) has 3 insiders with recent SEC Form 4 filings, including 3 buys and 9 sells. SNDX is classified in the Biotechnology industry within the Health Care sector.
Insider Ownership
| Role | Insider | Shares | Value | 30d |
|---|---|---|---|---|
| CEO | 484.8K | $9.21M | -6,847 | |
| CFO | 139.3K | $2.65M | -1,177 | |
| Dir | 0 | - | - |
Activity
Buys and sells only
Transactions
10 filings · page 2
| Date | Insider | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| May 19, 2025 | Goldan Keith A.53 | Chief Financial Officer | Buy | 3,000 | $0.00 | - | +3.3% | +70.6% | +108.2% | |
| May 16, 2025 | Botwood Nicholas A.J. | Head Of R&D, CMO | Buy | 11,765 | $9.00 | $105,826.17 | +50.3% | +62.8% | +123.5% | |
| Mar 4, 2025 | Metzger Michael A52 | Chief Executive Officer | Sale+OE | 7,814 | $15.05 | $117,563.97 | -2.5% | -23.6% | +50.3% | |
| Feb 10, 2025 | Goldan Keith A.53 | Chief Financial Officer | Sell | 3,777 | $15.50 | $58,558.61 | -4.0% | -27.4% | +40.9% | |
| Feb 10, 2025 | Metzger Michael A52 | Chief Executive Officer | Sell | 13,288 | $15.50 | $206,017.15 | -4.2% | -27.4% | +40.9% | |
| Feb 10, 2025 | Gallagher Neil | President, Head Of R&D | Sell | 4,618 | $15.50 | $71,597.47 | -5.1% | -27.4% | +40.9% | |
| Jun 14, 2024 | Goldan Keith A.53 | Chief Financial Officer | Buy | 1,250 | $20.03 | $25,037.25 | +2.4% | -10.5% | -49.0% | |
| Aug 9, 2023 | Morrison Briggs61 | Director | Sale+OE | 52,855 | $18.27 | $965,401.86 | -74.8% | -21.7% | +7.1% | |
| Aug 2, 2023 | Meury William | Director | Sale+OE | 83,000 | $20.46 | $1,697,810.00 | -36.6% | -31.3% | +7.4% | |
| Jul 10, 2023 | Morrison Briggs61 | Director | Sale+OE | 52,855 | $20.40 | $1,078,067.58 | -74.8% | -38.4% | +11.3% |